Precigen, Inc. (PGEN) stock
Close on Nov 12, 2026Market cap $1.67BP/E 116.5Yield –
Precigen, Inc. reported revenue of $156.94M for the twelve months to Sep 30, 2026. Free cash flow was -$74.32M. At the latest close the market valued the company at $1.67B, 116.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.67B
- P/E ratio
- 116.5
- Price to sales
- 10.63
- Price to book
- 19.91
- Dividend yield
- –
- Free cash flow yield
- -4.45%
Fundamentals
- Revenue
- $156.94M
- Net income
- $24.41M
- EPS, diluted
- $0.04
- Free cash flow
- -$74.32M
- Book value per share
- $0.20
- Diluted shares
- 421M
Trading
- Next earnings
- Mar 24, 2027 (estimated, during market hours)
- Previous close
- $4.72
- Open
- $4.70
- Day's range
- $4.59 – $4.91
- Volume
- 5,318,329
- Average volume (20 days)
- 7,985,690
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.64
- 52-week range
- $3.04 – $8.98
- RSI (14 days)
- 35.2
- Volatility (1 year)
- 85.3%
- Relative volume
- 0.96×
- WACC
- 13.0%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PGEN | S&P 500 | Difference | PGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -39.2% | -2.7% | −36.5 pts | ||
| 3 months | -32.0% | -1.7% | −30.2 pts | ||
| Year to date | +11.5% | +11.9% | −0.4 pts | ||
| 1 year | +15.9% | +12.0% | +3.9 pts | ||
| 3 years | +327.5% | +78.2% | +249.3 pts | +62.3% | +21.2% |
| 5 years | +7.6% | +73.2% | −65.6 pts | +1.5% | +11.6% |
| 10 years | -84.3% | +309.6% | −393.9 pts | -16.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Precigen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Precigen
Pharmaceutical Preparations
Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Utilizing platforms such as AdenoVerse, UltraVector, and UltraCAR-T, the company engineers gene programs and therapies targeting intractable conditions. Its first commercial product is Papzimeos, an adenoviral vector-based immunotherapy approved for treating adult recurrent respiratory papillomatosis. Precigen also maintains an investigational pipeline that includes PRGN-2009 for human papillomavirus-associated malignancies and PRGN-3006 for acute myeloid leukemia. Its offerings serve adult patients, healthcare providers, and integrated delivery networks managing rare diseases and oncology indications.
Company profile, executives and historyPrecigen stock: common questions
What is Precigen's stock price?
PGEN closed at $4.66 on Nov 12, 2026, down 1.27% on the day. Over the past 52 weeks it traded between $3.04 and $8.98.
What is Precigen's market cap?
Precigen was worth $1.67B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PGEN's P/E ratio?
PGEN trades at 116.5 times earnings, based on diluted earnings per share of $0.04 over the twelve months to Sep 30, 2026.
How much revenue does Precigen make?
Precigen reported revenue of $156.94M for the twelve months to Sep 30, 2026.
Does Precigen pay a dividend?
No. Precigen has not paid a cash dividend over the last twelve months.
When does Precigen report earnings next?
Precigen is expected to report Q4 FY2026 results on Mar 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PGEN stock performed over the past year?
Including dividends, PGEN returned +15.9% over the past year, against +12.0% for the S&P 500.
How many PGEN shares are sold short?
45M shares were sold short at the latest FINRA report, 22.77% of the float, or 8.6 days of average trading volume.
Who are Precigen's competitors?
Companies most similar to Precigen by business, industry and size include XNCR, FHTX, AGIO, MGNX, VSTM.
See a number that looks wrong?